William Blair upgrades Nektar on durability and deepening of rezpeg response

As previously reported, William Blair analyst Andy Hsieh upgraded Nektar (NKTR) to Outperform from Market Perform, citing the fact that that rezpegaldesleukin, or rezpeg, continues to demonstrate deepening of response and durability with longer-term data. With respect to durability, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing, notes the analyst, who also notes that there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg.